Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Analysis of the KRAS Mutant Cancer Pipeline, 2024: Emerging Therapies, Key Players, Unmet Needs and More
May 30, 2024 04:30 ET
|
Research and Markets
Dublin, May 30, 2024 (GLOBE NEWSWIRE) -- The "KRAS Mutant Cancer - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report outlays comprehensive...
[Latest] Global Colorectal Cancer Market Size/Share Worth USD 30,095.9 Million by 2033 at a 3.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 20, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, May 20, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Colorectal Cancer Market Size, Trends and Insights By Type of Treatment (Surgery,...
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
May 15, 2024 09:00 ET
|
Medigene AG
Planegg/Martinsried, May 15, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
May 08, 2024 16:02 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
May 02, 2024 16:05 ET
|
Cardiff Oncology, Inc.
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated...
Aanastra Inc to Showcase its Peptide-RNA Therapeutics Technology in Multiple Presentations at the American Society for Gene and Cell Therapies (ASGCT) Annual Meeting 2024
May 02, 2024 06:30 ET
|
Aanastra Inc
Aanastra showcases its peptide-RNA therapeutics targeting p53, KRAS and BRCA-1 driven cancers, hemophilia A and PCSK9 for hypercholestrolemia at ASGCT
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
May 02, 2024 02:30 ET
|
Medigene AG
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
May 01, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
April 24, 2024 07:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...